45.30CHF-3.51%Mkt Cap: 1.71B $P/E: —1d ago
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceut…
Industry Peers
Drug Manufacturers - Specialty & GenericIndicators:|
Key Statistics
Company
Market Cap1.71B $
Enterprise Value1.78B $
Revenue (TTM)444.34M $
Gross Profit75.94M $
Net Income (TTM)-24.16M $
Revenue/Share13.47 USD
Last Price45.30 CHF
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees1.4K
CountryCH
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)34.60
PEG—
EV/EBITDA41.00
EV/Revenue4.01
P/S3.84
P/B4.76
EPS (TTM)-0.59
EPS (Forward)1.31
52W Range
20.1084% of range50.10
52W High50.10 CHF
52W Low20.10 CHF
Profitability
Gross Margin16.98%
Oper. Margin9.99%
EBITDA Margin9.78%
Profit Margin-5.40%
ROE-6.22%
ROA-2.56%
Growth
Revenue Growth10.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF88.46M $
CapEx (TTM)124.29M $
FCF Margin-11.25%
FCF Yield-2.93%
Net Debt76.21M $
Net Debt/EBITDA1.75
Balance Sheet
Debt/Equity0.38
Current Ratio1.74
Quick Ratio0.87
Book Value/Sh9.525 CHF
Cash/Share2.260 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CHF
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateApr 28, 2022
Pay DateMay 2, 2022
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)38.64 CHF
Upside (mean)-14.7%
Target Range25.62 CHF – 45.13 CHF
CHF25.62-14.7% to meanCHF45.13
# Analysts6
Ownership
Shares Out.33.01M
Float12.96M
Insiders60.52%
Institutions12.44%
Technical
SMA 5040.40 (+12.1%)
SMA 20030.34 (+49.3%)
Beta1.04
S&P 52W Chg19.63%
Avg Vol (30d)53.85K
Avg Vol (10d)38.44K
Technical Indicators
RSI (14)55.8
MACD2.1359
MACD Signal2.4565
MACD Hist.-0.3206
BB Upper52.35 CHF
BB Middle45.07 CHF
BB Lower37.79 CHF
BB Width32.30%
ATR (14)1.945 CHF
Vol Ratio (20d)0.86x